Using miRNA-101 to Diagnose Liver Cancer in Egyptian Patients
Author Information
Author(s): Sharafeldin Mostafa A., Suef Reda A., Mousa Adel A., Ziada Dina H., Farag Mohamed M. S.
Primary Institution: Al-Azhar University
Hypothesis
The study aims to investigate the miRNA-101 differential expression in Egyptian HCV-induced HCC patients’ serum versus HCV liver cirrhosis as prospective diagnostic biomarkers compared to alpha-fetoprotein.
Conclusion
miR-101 is a promising non-invasive biomarker for the early detection of HCV-associated hepatocellular carcinoma in Egyptian patients.
Supporting Evidence
- miR-101 showed a 2.4-fold increase in HCC patients compared to healthy controls.
- miR-101 had a sensitivity of 92.5% and specificity of 97.5% for diagnosing HCC.
- Elevated miR-101 levels correlated with larger tumor sizes and advanced disease stages.
Takeaway
Researchers found that a molecule called miR-101 in the blood can help doctors tell if someone has liver cancer caused by hepatitis C, which is really important for catching the disease early.
Methodology
The study involved a retrospective case-control design with blood samples collected from 100 subjects, including HCV-induced HCC patients, cirrhosis patients, and healthy controls, with miR-101 levels evaluated using RT-qPCR.
Limitations
The study's cross-sectional design limits the ability to assess the prognostic value of miR-101 over time.
Participant Demographics
The study included 40 HCV-induced HCC patients (23 male, 17 female), 40 HCV-induced cirrhosis patients (26 male, 14 female), and 20 healthy controls (11 male, 9 female).
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI: 0.909 — 1.002
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website